% | $
Quotes you view appear here for quick access.

Calmare Therapeutics Incorporated Message Board

  • favela808 favela808 Mar 11, 2013 10:12 AM Flag

    Mayo Clinic increases Size of Calmare (Scrambler Therapy) Study from 100 to 150

    Study Type: Interventional
    Study Design: Endpoint Classification: Safety/Efficacy Study
    Intervention Model: Single Group Assignment
    Masking: Open Label
    Primary Purpose: Supportive Care
    Official Title: Scrambler Therapy for the Treatment of Chemotherapy Induced Peripheral Neuropathy: An Open Access Trial

    Resource links provided by NLM:

    Genetics Home Reference related topics: Charcot-Marie-Tooth disease hereditary neuropathy with liability to pressure palsies
    MedlinePlus related topics: Peripheral Nerve Disorders
    U.S. FDA Resources

    Further study details as provided by Mayo Clinic:

    Primary Outcome Measures:
    Change in pain on a 0-10 numerical rating scale. [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

    Secondary Outcome Measures:
    Changes in neurologic function will be done by Neurometer Current Perception Threshold (CPT) testing and with a Rydel-Seiffer graduated tuning fork. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    Patients will also undergo neurologic function testing. This will be done in an exploratory measure to try to correlate changes in the patient reported outcome instrument data with changes in the different measures of neurologic function. The two measures will be Neurometer Current Perception Threshold (CPT) Testing and testing with a Rydel-Seiffer graduated tuning fork.

    Estimated Enrollment: 150

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • succhiacazzo Mar 13, 2013 9:06 AM Flag

      What? They couldn't prove anything with 100 patients, so they go fishing by recruiting MORE patients?

      Personally, I'd be more interested in seeing Dr. Campbell's results -- the results that were originally due a YEAR ago but which were postponed THREE times and were SUPPOSED to be available back in NOVEMBER -- over THREE MONTHS ago -- but of which not so much as a single word has been heard.

      Certainly, the recent release of Dr. Swainey's results haven't generated much excitement now, have they?

      Sentiment: Strong Sell

0.1540.000(0.00%)Oct 19 1:17 PMEDT